Cancer cell toxicity to therapeutic H 2 O 2 varies widely depending on cell type. Interestingly, it has been observed that different cancer cell types have varying peroxiporin expression. We hypothesize that variation in peroxiporin expression can alter cell susceptibility to therapeutic H 2 O 2 concentrations. Here, we silence peroxiporin aquaporin-3 (AQP3) on the pancreatic cancer cell line MIA PaCa-2 and compare clonogenic survival response to the wild-type. The results showed a significantly higher surviving fraction in the clonogenic response for siAQP3 MIA PaCa-2 cells at therapeutic H 2 O 2 doses (P < 0.05). These results suggest that peroxiporin expression is significant in modulating the susceptibility of cancer cells to ascorbate therapy.
Introduction
Recent preclinical studies and a Phase I clinical trial [1] [2] [3] [4] have demonstrated promise in the use of the pro-drug pharmacological ascorbate (P-AscH -) as an adjuvant in the treatment of pancreatic ductal adenocarcinoma. Intravenous infusions of P-AscH -(plasma concentrations of %20 mM) decreased tumor volume and suggested increased survival of patients with stage 4 pancreatic cancer [3] . P-AscH -has promise for improving outcomes for pancreatic cancer patients; however, its broad application for other types of cancer has yet to be realized. The impotence in moving forward with P-AscH -therapy for patients with other types of cancer is due, in part, to observations in a recent in vitro study by Chen et al. (2008) [5] . There, they reported that while normal cells remain relatively unaffected to P-AscH -, cancer cell lines exhibit a wide range of responses as seen by rates of clonogenic survival. Therefore, it is of great interest to understand why certain cancer cells are more responsive to P-AscH -and thereby guide the use of P-AscH -as an adjuvant to cancer therapy. a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
Extracellular H 2 O 2 is Primary Factor in Ascorbate Therapy Efficacy
The mechanism behind ascorbate mediated cell death is being studied extensively [1, [5] [6] [7] [8] [9] . The work developed from understanding the unique nature of ascorbate and its ability to serve as an anti-oxidant (at low physiological concentrations) compared to its pro-oxidant behavior (at pharmacological concentrations) [5, 10] . It is now clear that at higher concentrations (achievable through intravenous administrations), ascorbate undergoes autoxidation and readily forms H 2 O 2 . Furthermore, the presence of catalytic metals (i.e. iron) serves to accelerate this process [11] . In addition to the biochemical nature of ascorbate, a tremendous amount of work has been directed into discovering the variation in enzymatic activity of ascorbate-susceptible cells [10, 12] . In order to unveil the mechanism of ascorbate-mediated cell death, a significant amount of research has worked on understanding the type of cell death induced (apoptosis, autophagy, etc.) [10, 13] and the intracellular damage (metabolic, nuclear, etc.) [12] that occurs. It was further confirmed that cytotoxicity was a result of extracellular and not intracellular ascorbate [14, 15] . Furthermore, numerous in vivo and in vitro studies have displayed a range of susceptibility to P-AscH -across different types of cancer [1, 5, 13, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , and intracellular H 2 O 2 , being the byproduct of P-AscH -oxidation, has been identified as the primary factor for cellular cytotoxicity. Thus, ascorbate is categorized as a pro-drug due to its ability to generate high concentrations of extracellular hydrogen peroxide (H 2 O 2 ) that permeates into the intracellular space [4, 10, 14, 15] . It has been demonstrated that the effects of P-AscH -are reversible with the intro- [33, 34] . The AQP isoforms currently identified that allow passive transport of H 2 O 2 are AQP1, AQP3, and AQP8 [33, 35] . AQPs are heavily expressed in many types of tumors [36] , especially those considered aggressive [37] . Thus, it is hypothesized that increased plasma membrane permeability to extracellular H 2 O 2 (i.e., via enhanced expression of peroxiporins) can further increase the efficacy of P-AscH -therapy.
In this work, we investigate the significance of plasma membrane H 2 O 2 permeability to in vitro cell susceptibility to therapeutic extracellular H 2 O 2 concentrations. In particular, the clonogenic surviving fraction response for the pancreatic cancer cell line MIA PaCa-2 with modified peroxiporin expression is evaluated. Initially the expression of AQP1, AQP3, and AQP8 of MIA PaCa-2 are qualitatively screened against the normal pancreatic tissue cell line H6c7 using an immunocytochemistry assay. Recognizing that AQP3 is substantially overexpressed in MIA PaCa-2, the study focuses on silencing AQP3 (siAQP3 MIA PaCa-2). Next the relative expression levels of AQP3 for both siAQP3 MIA PaCa-2 and unmodified MIA PaCa-2 using flow cytometry is verified. In addition, the rate of H 2 O 2 uptake and cell susceptibility between the two cell lines are compared. Finally, the clonogenic surviving fraction for exposure to therapeutic H 2 O 2 concentrations is evaluated for siAQP3 MIA PaCa-2 and unmodified MIA PaCa-2. The results of this study show that AQP3 expression is significant in the clonogenic surviving fraction response for MIA PaCa-2 for in vitro therapeutic exposure to H 2 O 2 . These results emphasize the importance of considering plasma membrane permeability to H 2 O 2 when elucidating cellular properties that can impact the response of cells to exposure to extracellular H 2 O 2 and the success of P-AscH -as an adjuvant to cancer therapies.
Materials and Methods

Antibodies
The following antibodies were used in this study for immunocytochemistry and flow cytome 
Cells and Reagents
Pancreatic H6c7 cells (HPV16-E6E7) [38] were established by transduction of HPV16-E6E7 genes into a primary culture of normal pancreatic duct epithelial cells and cultured in keratinocyte SFM (KSFM, Invitrogen, Carlsbad, CA) with supplements: human recombinant epidermal growth factor and bovine pituitary extract (Life Technologies, Carlsbad, CA, USA), in addition to 1% antibiotics. Pancreatic adenocarcinoma MIA PaCa-2 cells (American Type Culture Collection Manassas, VA) were cultured in Dulbecco's Modified Eagle's Medium (DMEM, Life Technologies, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS, Life
Technologies, Carlsbad, CA, USA) and 1% antibiotic. All cells were maintained at incubation of 37˚C and supplied with 5% CO 2 and 1% penicillin streptomycin (Life Technologies, Carlsbad, CA, USA).
Immunocytochemistry Staining
Cells were seeded on glass cover slips (ThermoFisher Scientific, Lafayette, CO, USA) 48 h before fixing with paraformaldehyde (4% PFA) for 15 min. PFA was removed by three 5-min 1x PBS washes. Normal goat serum (5% NGS) diluted in 1x PBS was added to cells for 1 h at room temperature (RT) on a shaker to block non-specific binding. Primary antibodies diluted 1:200 in 0.3% Triton X 100 (in PBS) were added to cells and left to gently shake for 12 h in 4˚C. Primary antibodies were removed via three 5-min 1x PBS washes. Secondary antibodies diluted 1:100 in NGS were added to cells and placed on shaker for 2 h RT. Secondary antibodies were removed by three 5-min 1x PBS washes and glass coverslips containing stained cells were mounted on microscope slides (ThermoFisher Scientific, Lafayette, CO, USA 
Silencing AQP3 on MIA PaCa-2 Cells
Silencing was accomplished through reverse transfection using double stranded siRNA, siRNA AQP3 (s1523; Invitrogen, Carlsbad, CA). The protocol provided by Invitrogen was adjusted appropriately. A total of 6 pmol siRNA AQP3 (20 μL or 500 μL) were diluted in Opti-MEM I Reduced Serum Medium (31985-062; Life Technologies, Carlsbad, CA, USA) then added and evenly spread in wells. Following with the addition of Lipofectamine RNAiMAX (133778-150; Life Technologies, Carlsbad, CA, USA) (0.3 μL or 5 μL) and thoroughly mixed to each, 96-or 6-well plates, containing the diluted siRNA molecules. The siRNA and Lipofectamine were allowed to interact 10-20 min at RT to allow siRNA-lipid complex formation. Cells were diluted in appropriate complete growth medium and cell density reached 30-50% confluency 24 h after plating. Plates were gently mixed. Plates were incubated for 48 h at 37˚C with 5% CO 2 supplied. The transfection efficiency was obtained for MIA PaCa-2 using siRNA Cy-3 GAPDH (Life Technologies, Carlsbad, CA, USA) in place of siAQP3 strands and serves as a positive control for the method of silencing. Successfully transfected cells were visualized using ArcturusXT LCM System (ThermoFisher Scientific, Lafayette, CO, USA) and counted using disposable hemocytometers (INCYTO, Covington, GA, USA). Scrambled siRNA AQP3 (4390843; Life Technologies, Carlsbad, CA, USA) sequences were used for the negative control of each experimental set up to ensure that the silencing procedure was not affecting results. The scrambled siRNA sequences were delivered to the cells in an identical manner as the siRNA AQP3 with the same concentrations of each component and identical cell plating number.
Relative AQP3 Expression
Flow cytometric analysis was performed to obtain quantification in fluorescent signal reduction for AQP3 between MIA PaCa-2 unmodified and siAQP3 MIA PaCa-2 cells. ; representative of 0, 50, 60, 70, 80 and 90 μM) [40] were diluted in the appropriate culture media and cells were exposed for 1 h at 37˚C. After exposure, the diluted media was removed, cells were trypsinized and counted with a Moxi Z Mini Automated Cell Counter (ORFLO Technologies, Ketchum, ID, USA) and re-plated at 300 cells mL - 
Results
Immunocytochemistry Staining for Peroxiporins
We conducted immunocytochemistry staining to verify the presence of peroxiporins AQP1, AQP3, and AQP8 for MIA PaCa-2 and H6c7 cells. In addition to verifying the presence of these peroxiporins, the signal intensities evaluated from immunocytochemistry also allowed for a qualitative measurement for the relative expression levels for each peroxiporin on both cell types. Elevated signal intensities indicate greater presence of these proteins and therefore elevated expression. Images of the immunocytochemistry staining for AQP1, AQP3, and AQP8 in H6c7 and MIA PaCa-2 cell, allow qualitative assessment for AQP expression of each cell type. Quantification shows the variation in expression of each of the AQPs between the two cell-types providing insight as to which peroxiporin is more highly expressed by MIA PaCa-2 cancer cells, Fig 1. Differences in expression of peroxiporin AQP1, is not apparent between H6c7 and MIA cells. Although AQP8 has a higher expression in MIA PaCa-2 compared to H6c7 cells, it is clear that AQP3 is significantly more elevated in MIA PaCa-2 cells compared to H6c7 cells. This study therefore focuses on the significance of AQP3.
Silencing Reduces AQP3 on the Plasma Membrane
To examine the role of AQP3 in modulating the rate of uptake of extracellular H 2 O 2 by MIA PaCa-2 cells we used siAQP3 as a tool to modulate AQP3 expression. Flow cytometric analysis was used to verify the silencing of peroxiporin AQP3 on the plasma membrane. We were able to confirm a factor of 10 relative decrease in peroxiporin AQP3 expression for the silenced cells by obtaining AQP3 specific signals for wild-type unmodified MIA PaCa-2 vs. silenced AQP3. 
Rate of Uptake of Extracellular H 2 O 2
The rate of exogenous H 2 O 2 uptake was determined for MIA PaCa-2 and siAQP3 MIA PaCa-2 cells using a kinetic assay described previously [39] . The rate constant for the uptake of extracellular H 2 O 2 per cell is significantly decreased for siAQP3 MIA PaCa-2 as compared to MIA PaCa-2 cells (P = 0.002, n = 4), Fig 3. This confirms that AQP3 is an important factor in controlling the flux of H 2 O 2 through the plasma membrane. Scrambled siRNA for AQP3 (negative control) displayed no significant difference for the rate of H 2 O 2 uptake when compared to MIA PaCa-2 unmodified cells (P = 0.41, n = 4). (90 μM) (P = 0.02, n = 3). These results indicate that the AQP3, which facilitates the permeability of H 2 O 2 across the plasma membrane, is an important determinant of the toxicity of H 2 O 2 ; AQP3 expression appears to be a significant factor in the outcome of ascorbate therapy.
Discussion
While pancreatic cancer cells exhibit significantly reduced proliferation in the presence of extracellular P-AscH - [1] , and normal cells remain unaffected, other cancer cells exhibit a wide variation in susceptibility. Previously, a focus for the underlying differences in susceptibility to P-AscH -has been on the varying catalase activity across cell types [1, 10] . Catalase serves as an Our results show that AQP3 acts as a conduit for the flux of H 2 O 2 into the cell [10] . However, a more complete analysis is required for understanding overall flux contributions from variation in permeability to H 2 O 2 as well as catalase activity.
The overall intracellular concentration of H 2 O 2 in normal cells is likely to be substantially less than in pancreatic cancer tumor cells during therapy with P-AscH -. Thus, the removal rate of H 2 O 2 is likely to be substantially higher for H6c7 cells as opposed to MIA PaCa-2 once it has crossed the plasma membrane. But, in addition, the results from Fig 1 imply that the permeability of H 2 O 2 , at least through the available peroxiporins, is also substantially reduced for H6c7 cells as compared to MIA PaCa-2. This further suggests that the expression of peroxiporins may be also linked to the susceptibility of cells to the H 2 O 2 generated by P-AscH -. Thus, those cancer cells that are most susceptible may have an increased expression of peroxiporin in addition to a lower relative catalase activity compared to normal cells.
We show that silencing a peroxiporin, specifically AQP3, inhibits the passage of H 2 O 2 into the cell. Additionally, and more importantly, the silencing of peroxiporin AQP3 on pancreatic cancer cells suggests that accumulation of lethal intracellular H 2 O 2 concentrations is prevented; consequently, allowing for an increase in clonogenic response. Silencing peroxiporin AQP3 resulted in an increase in surviving fraction of siAQP3 MIA PaCa-2 cells in a clonogenic assay using pharmacological H 2 [15] . In that study the extracellular ascorbate reached 34 mM.
Overall, this work demonstrates that the permeability of the plasma membrane to H 2 O 2 is an important factor when addressing the efficacy of P-AscH -as an adjuvant to cancer therapy.
Although extensive research would be required, modulating membrane peroxiporin expression may increase the efficacy of P-AscH -as an adjuvant for other types of cancer. As a side note, some drugs, such as gemcitabine used for pancreatic cancer, are known to elevate peroxiporin, specifically AQP3, expression in cancer cells [3, 43] . This additional factor may be significant for expanding the use of P-AscH -therapy for other forms of cancer. 
Implications for Ascorbate Therapy
